Theragnostic liposomes for the diagnosis and treatment of tuberculosis

Rebeca Jiménez-Rodríguez; Janna Douda; I. I. Mota-Díaz; Julieta Luna-Herrera; I. C. Romera-Ibarra; J. L. Casas-Espínola

doi:10.1557/s43580-023-00496-3

Theragnostic liposomes for the diagnosis and treatment of tuberculosis

Rebeca Jiménez-Rodríguez, Janna Douda, I. I. Mota-Díaz, Julieta Luna-Herrera, I. C. Romera-Ibarra, J. L. Casas-Espínola

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The indiscriminate use of antibiotics has generated super bacteria resistant to many conventional drugs. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis, the use of conventional treatments for this disease generates significant damage to the liver and kidney functions of patients, which is why treatments are required that allow early diagnosis and selectivity for Pathogenic bacteria. In this work, a drug currently used for the treatment of tuberculosis (rifampicin) and silver nanoparticles as luminescent biomarkers are being encapsulated, and estimated by means of UV–VIS, FTIR, and DLS techniques for the design of theragnostic liposomes. The results show that this type of liposomes have important characteristics to be used as elements of early diagnosis in addition to its possible therapeutic use. Graphical abstract: [Figure not available: see fulltext.]

Original language	English
Pages (from-to)	67-70
Number of pages	4
Journal	MRS Advances
Volume	8
Issue number	3
DOIs	https://doi.org/10.1557/s43580-023-00496-3
State	Published - Apr 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1557/s43580-023-00496-3

Cite this

@article{7376d7944a2e4b078357c6837d2aa0da,

title = "Theragnostic liposomes for the diagnosis and treatment of tuberculosis",

abstract = "The indiscriminate use of antibiotics has generated super bacteria resistant to many conventional drugs. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis, the use of conventional treatments for this disease generates significant damage to the liver and kidney functions of patients, which is why treatments are required that allow early diagnosis and selectivity for Pathogenic bacteria. In this work, a drug currently used for the treatment of tuberculosis (rifampicin) and silver nanoparticles as luminescent biomarkers are being encapsulated, and estimated by means of UV–VIS, FTIR, and DLS techniques for the design of theragnostic liposomes. The results show that this type of liposomes have important characteristics to be used as elements of early diagnosis in addition to its possible therapeutic use. Graphical abstract: [Figure not available: see fulltext.]",

author = "Rebeca Jim{\'e}nez-Rodr{\'i}guez and Janna Douda and Mota-D{\'i}az, {I. I.} and Julieta Luna-Herrera and Romera-Ibarra, {I. C.} and Casas-Esp{\'i}nola, {J. L.}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive licence to The Materials Research Society.",

year = "2023",

month = apr,

doi = "10.1557/s43580-023-00496-3",

language = "Ingl{\'e}s",

volume = "8",

pages = "67--70",

journal = "MRS Advances",

issn = "2059-8521",

publisher = "Materials Research Society",

number = "3",

}

TY - JOUR

T1 - Theragnostic liposomes for the diagnosis and treatment of tuberculosis

AU - Jiménez-Rodríguez, Rebeca

AU - Douda, Janna

AU - Mota-Díaz, I. I.

AU - Luna-Herrera, Julieta

AU - Romera-Ibarra, I. C.

AU - Casas-Espínola, J. L.

PY - 2023/4

Y1 - 2023/4

N2 - The indiscriminate use of antibiotics has generated super bacteria resistant to many conventional drugs. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis, the use of conventional treatments for this disease generates significant damage to the liver and kidney functions of patients, which is why treatments are required that allow early diagnosis and selectivity for Pathogenic bacteria. In this work, a drug currently used for the treatment of tuberculosis (rifampicin) and silver nanoparticles as luminescent biomarkers are being encapsulated, and estimated by means of UV–VIS, FTIR, and DLS techniques for the design of theragnostic liposomes. The results show that this type of liposomes have important characteristics to be used as elements of early diagnosis in addition to its possible therapeutic use. Graphical abstract: [Figure not available: see fulltext.]

AB - The indiscriminate use of antibiotics has generated super bacteria resistant to many conventional drugs. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis, the use of conventional treatments for this disease generates significant damage to the liver and kidney functions of patients, which is why treatments are required that allow early diagnosis and selectivity for Pathogenic bacteria. In this work, a drug currently used for the treatment of tuberculosis (rifampicin) and silver nanoparticles as luminescent biomarkers are being encapsulated, and estimated by means of UV–VIS, FTIR, and DLS techniques for the design of theragnostic liposomes. The results show that this type of liposomes have important characteristics to be used as elements of early diagnosis in addition to its possible therapeutic use. Graphical abstract: [Figure not available: see fulltext.]

UR - http://www.scopus.com/inward/record.url?scp=85146387141&partnerID=8YFLogxK

U2 - 10.1557/s43580-023-00496-3

DO - 10.1557/s43580-023-00496-3

M3 - Artículo

AN - SCOPUS:85146387141

SN - 2059-8521

VL - 8

SP - 67

EP - 70

JO - MRS Advances

JF - MRS Advances

IS - 3

ER -

Theragnostic liposomes for the diagnosis and treatment of tuberculosis

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this